|
KMID : 1001020060040020078
|
|
Journal of Urologic Oncology
2006 Volume.4 No. 2 p.78 ~ p.83
|
|
|
The Prognostic Factors in Patients with Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy
|
|
Kim Jung-Man
Lee Chang-Yell
Ha Hong-Koo
Chung Moon-Kee
|
|
|
Abstract
|
|
|
Purpose: The prognostic factors in patients with metastatic prostate cancer after androgen deprivation treatment was assessed retrospectively.
Materials and Methods : Senventy patients with metastatic prostatic cancer treated with androgen deprivation therapy were included in this study. Variety of possible prognostic factors, such as age, pretreatment serum prostate specific antigen(PSA), Gleason score, value of nadir serum PSA, duration to nadir serum PSA and treatment modality were analyzed.
Results: Mean age of patients was 70.5?8.9(56-90) years old and 16 patients were expired, who’s mean survival time was 27.2?14.1(6-97) months and mean survival time of patients who are alive was 27.6?21.2(6-82) months. Mean survival time of pretreatment serum PSA level of 0-3.99ng/ml, 4-9.99ng/ml, 10-99.99ng/ml, 100-499.99ng/ml and ＞500ng/ml was 49.0, 34.1, 25.2, 29.9 and 21.6 months, repectively. Mean survival time of nadir serum PSA of 0-0.02ng/ml, 0.21-4ng/ml and ＞4ng/ml was 29.8, 27.1, and 21.8 months, repectively. But Age, Gleason score, duration to nadir serum PSA and treatment modality did not relate significantly with survival.
Conclusions : The results of present study suggest that pretreatment serum PSA and value of nadir serum PSA are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with androgen deprivation therapy.
|
|
|
KEYWORD
|
|
|
Prostate cancer, Hormone therapy, Prognosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|